Cagrilintide Dosage: Reported Research Ranges
Reported in research: 0.3–4.5 mg once weekly (subcutaneous) in published human trials, with 2.4 mg the amount used in the phase 3 trials; practitioner protocols report 300 mcg–4.5 mg weekly. Sources broadly agree.
Dosing Protocols Research · Peptide dosage chart · What is Cagrilintide? · Research library
Reported ranges by source
| Reported range | Source type | Evidence strength |
|---|---|---|
| 0.3–4.5 mg once weekly, subcutaneous (arms of 0.3, 0.6, 1.2, 2.4 and 4.5 mg) | Human trial (published study) | Human: randomized controlled trials |
| 2.4 mg once weekly, alone or with semaglutide 2.4 mg | Human trial (published study) | Human: phase 3 randomized controlled trials |
| 300 mcg–4.5 mg once weekly | Practitioner protocols | Practitioner protocol (not a clinical trial) |
Amounts are shown as each source reports them. Where sources disagree, the table lists each one; there is no single agreed amount.
Published human trials in our library
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial · PubMed 34798060
- Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants · PubMed 39279639
- Efficacy and safety of co-administered once-weekly cagrilintide 2·[amount hidden] with once-weekly semaglutide 2·[amount hidden] in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial · PubMed 37364590
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity · PubMed 40544433
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes · PubMed 40544432
- CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 · PubMed 41328546
- Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study · PubMed 42251859
FAQ
What Cagrilintide dosage is reported in research?
Reported in research: 0.3–4.5 mg once weekly (subcutaneous) in published human trials, with 2.4 mg the amount used in the phase 3 trials; practitioner protocols report 300 mcg–4.5 mg weekly. Sources broadly agree.
Is there human-trial evidence for Cagrilintide dosing?
Yes. Published randomized trials in our study library report the amounts in the table above.
Why do the reported Cagrilintide amounts differ?
Each source studied or described a different group, form, goal and time frame, so reported amounts vary between sources. PeptideWhiz lists each one with its source type instead of picking a single amount.
Where can I convert a Cagrilintide amount into syringe units?
The PeptideWhiz calculator for Cagrilintide converts a vial amount, water volume and target amount into mL and syringe units. It does not suggest an amount.
Last updated: November 2, 2026.
Research information only. This page lists amounts as reported in published studies, practitioner protocols and Dr. Trevor reports. It is not medical advice and not a recommendation for any person. Sources vary, and most of these compounds are not approved for the uses discussed.